Background: Elastic chest wall restriction introduced by Chevaillier is thought to reduce existing hyperinflation and improve mucus clearance from peripheral airways. In healthy adults, restriction decreases the functional residual capacity (FRC) and forced vital capacity (FVC), while ventilation inhomogeneity (lung clearance index [LCI]) increases. Pulmonary function response to restriction is unknown in individuals with cystic fibrosis (CF). Objectives: To examine short-term effects of elastic chest wall restriction on pulmonary function in children with CF. Methods: Pulmonary function was first assessed twice 15 min apart at baseline and then again following 15 min of elastic chest wall restriction in 20 school-aged children with CF (12.3 ± 3.4 years). Primary outcomes were LCI from nitrogen multiple-breath washout, residual volume (RV), and FRC from plethysmography. Secondary outcomes were FVC and end-expiratory lung impedance (EELI) from electrical impedance tomography. Endpoints were test-retest reliability at baseline and lung function response to restriction, both on group and individual levels. Results: Test-retest reliability was excellent (intra-class correlation coefficients range 0.84–0.99). Following restriction, FRC significantly declined on average (95% CI) by –0.09 (–0.17 to –0.02) L. Similarly, FVC declined while LCI did not change. RV and EELI declined, but this did not reach statistical significance. On the individuals’ level, heterogeneous changes in pulmonary function occurred following elastic chest wall restriction. Conclusions: These findings indicate that the application of elastic chest wall restriction is safe, induces the intended decline in resting lung volume but does not systematically alter ventilation inhomogeneity in children with CF.

Keywords:
Cystic fibrosis, Physical therapy modalities, Physiotherapy, Pulmonary function test
1.
Daniels T, Morrison L, Harnett N, Lewis S; Members of the Physiotherapy Working Group: Standards of Care and Good Clinical Practice for the Physiotherapy Management of Cystic Fibrosis, ed 3. Cystic Fibrosis Trust, 2017, pp 20–27.
2.
Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A, Flume P, Kashirskaya N, Munck A, Ratjen F, Schwarzenberg SJ, Sermet-Gaudelus I, Southern KW, Taccetti G, Ullrich G, Wolfe S: European cystic fibrosis society standards of care: best practice guidelines. J Cyst Fibros 2014; 13(suppl 1):S23–S42.
3.
Chevaillier J, van Ginderdeuren F; International Physiotherapy Group for Cystic Fibrosis: Blue booklet: physiotherapy in the treatment of CF, ed 4. IPG/CF, 2009, pp 8–11.
4.
Schöni MH: Autogenic drainage: a modern approach to physiotherapy in cystic fibrosis. J R Soc Med 1989; 82: 32–37.
5.
Chapman DG, Berend N, Horlyck KR, King GG, Salome CM: Does increased baseline ventilation heterogeneity following chest wall strapping predispose to airway hyperresponsiveness? J Appl Physiol (1985) 2012; 113: 25–30.
6.
Pellegrino R, Pompilio PP, Bruni GI, Scano G, Crimi C, Biasco L, Coletta G, Cornara G, Torchio R, Brusasco V, Dellaca RL: Airway hyperresponsiveness with chest strapping: a matter of heterogeneity or reduced lung volume? Respir Physiol Neurobiol 2009; 166: 47–53.
7.
Torchio R, Gulotta C, Ciacco C, Perboni A, Guglielmo M, Crosa F, Zerbini M, Brusasco V, Hyatt RE, Pellegrino R: Effects of chest wall strapping on mechanical response to methacholine in humans. J Appl Physiol (1985) 2006; 101: 430–438.
8.
Miller JD, Beck KC, Joyner MJ, Brice AG, Johnson BD: Cardiorespiratory effects of inelastic chest wall restriction. J Appl Physiol (1985) 2002; 92: 2419–2428.
9.
Coast JR, Cline CC: The effect of chest wall restriction on exercise capacity. Respirology 2004; 9: 197–203.
10.
Kraemer R, Baldwin DN, Ammann RA, Frey U, Gallati S: Progression of pulmonary hyperinflation and trapped gas associated with genetic and environmental factors in children with cystic fibrosis. Respir Res 2006; 7: 138.
11.
Yammine S, Singer F, Gustafsson P, Latzin P: Impact of different breathing protocols on multiple-breath washout outcomes in children. J Cyst Fibros 2014; 13: 190–197.
12.
Zhao Z, Fischer R, Frerichs I, Muller-Lisse U, Moller K: Regional ventilation in cystic fibrosis measured by electrical impedance tomography. J Cyst Fibros 2012; 11: 412–418.
13.
Davies J, Sheridan H, Bell N, Cunningham S, Davis SD, Elborn JS, Milla CE, Starner TD, Weiner DJ, Lee PS, Ratjen F: Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. Lancet Respir Med 2013; 1: 630–638.
14.
Singer F, Kieninger E, Abbas C, Yammine S, Fuchs O, Proietti E, Regamey N, Casaulta C, Frey U, Latzin P: Practicability of nitrogen multiple-breath washout measurements in a pediatric cystic fibrosis outpatient setting. Pediatr Pulmonol 2013; 48: 739–746.
15.
Robinson PD, Latzin P, Verbanck S, Hall GL, Horsley A, Gappa M, Thamrin C, Arets HG, Aurora P, Fuchs SI, King GG, Lum S, Macleod K, Paiva M, Pillow JJ, Ranganathan S, Ratjen F, Singer F, Sonnappa S, Stocks J, Subbarao P, Thompson BR, Gustafsson PM: Consensus statement for inert gas washout measurement using multiple- and single-breath tests. Eur Respir J 2013; 41: 507–522.
16.
Robinson PD, Goldman MD, Gustafsson PM: Inert gas washout: theoretical background and clinical utility in respiratory disease. Respiration 2009; 78: 339–355.
17.
Yammine S, Nyilas S, Casaulta C, Schibli S, Latzin P, Sokollik C: Function and ventilation of large and small airways in children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis 2016; 22: 1915–1922.
18.
Yorkey TJ, Webster JG, Tompkins WJ: Comparing reconstruction algorithms for electrical impedance tomography. IEEE Trans Biomed Eng 1987; 34: 843–852.
19.
Schnidrig S, Casaulta C, Schibler A, Riedel T: Influence of end-expiratory level and tidal volume on gravitational ventilation distribution during tidal breathing in healthy adults. Eur J Appl Physiol 2013; 113: 591–598.
20.
Wettstein M, Radlinger L, Riedel T: Effect of different breathing aids on ventilation distribution in adults with cystic fibrosis. PLoS One 2014; 9:e106591.
21.
Zhao Z, Moller K, Steinmann D, Frerichs I, Guttmann J: Evaluation of an electrical impedance tomography-based Global Inhomogeneity Index for pulmonary ventilation distribution. J Intensive Care Med 2009; 35: 1900–1906.
22.
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J: Standardisation of spirometry. Eur Respir J 2005; 26: 319–338.
23.
Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson D, Macintyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G: Standardisation of the measurement of lung volumes. Eur Respir J 2005; 26: 511–522.
24.
Nyilas S, Singer F, Kumar N, Yammine S, Meier-Girard D, Koerner-Rettberg C, Casaulta C, Frey U, Latzin P: Physiological phenotyping of pediatric chronic obstructive airway diseases. J Appl Physiol (1985) 2016; 121: 324–332.
25.
Flegal KM, Cole TJ: Construction of LMS parameters for the Centers for Disease Control and Prevention 2000 growth charts. Natl Health Stat Report 2013; 63: 1–3.
26.
Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, Stocks J: Multi-ethnic reference values for spirometry for the 3–95-years age range: the global lung function 2012 equations. Eur Respir J 2012; 40: 1324–1343.
27.
Koopman M, Zanen P, Kruitwagen CL, van der Ent CK, Arets HG: Reference values for paediatric pulmonary function testing: the utrecht dataset. Respir Med 2011; 105: 15–23.
28.
Shrout PE, Fleiss JL: Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979; 86: 420–428.
29.
Cuzick J: A Wilcoxon-type test for trend. Stat Med 1985; 4: 87–90.
30.
Raaijmakers L, Jensen R, Stanojevic S, Ratjen F: Validation of multiple breath washout devices. J Cyst Fibros 2017; 16:e22–e23.
31.
Sonnappa S, Bastardo CM, Wade A, Bush A, Stocks J, Aurora P: Repeatability and bronchodilator reversibility of lung function in young children. Eur Respir J 2013; 42: 116–124.
32.
Amin R, Subbarao P, Jabar A, Balkovec S, Jensen R, Kerrigan S, Gustafsson P, Ratjen F: Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax 2010; 65: 379–383.
33.
Grosse-Onnebrink J, Mellies U, Olivier M, Werner C, Stehling F: Chest physiotherapy can affect the lung clearance index in cystic fibrosis patients. Pediatr Pulmonol 2017; 52: 625–631.
34.
Poncin W, Reychler G, Leeuwerck N, Bauwens N, Aubriot AS, Nader C, Liistro G, Gohy S: Short-term effect of autogenic drainage on ventilation inhomogeneity in adult subjects with stable non-cystic fibrosis bronchiectasis. Respir Care 2017; 62: 524–531.
35.
Grillo L, Irving S, Hansell DM, Nair A, Annan B, Ward S, Bilton D, Main E, Davies J, Bush A, Wilson R, Loebinger MR: The reproducibility and responsiveness of the lung clearance index in bronchiectasis. Eur Respir J 2015; 46: 1645–1653.
36.
Pfleger A, Steinbacher M, Schwantzer G, Weinhandl E, Wagner M, Eber E: Short-term effects of physiotherapy on ventilation inhomogeneity in cystic fibrosis patients with a wide range of lung disease severity. J Cyst Fibros 2015; 14: 627–631.
37.
Fuchs SI, Toussaint S, Edlhaimb B, Ballmann M, Gappa M: Short-term effect of physiotherapy on variability of the lung clearance index in children with cystic fibrosis. Pediatr Pulmonol 2010; 45: 301–306.
38.
Abbas C, Singer F, Yammine S, Casaulta C, Latzin P: Treatment response of airway clearance assessed by single-breath washout in children with cystic fibrosis. J Cyst Fibros 2013; 12: 567–574.
39.
Nyilas S, Bauman G, Sommer G, Stranzinger E, Pusterla O, Frey U, Korten I, Singer F, Casaulta C, Bieri O, Latzin P: Novel magnetic resonance technique for functional imaging of cystic fibrosis lung disease. Eur Respir J 2017; 50:pii: 1701464.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.